Wissenschaftliche Mitarbeiter

Prof. Dr. sc. hum. Ulrike Haug

Lebenslauf

Wissenschaftlicher Werdegang
  • Seit 2015 W3-Professur für Klinische Epidemiologie und Pharmako-epidemiologie an der Universität Bremen und Leiterin der Abteilung Klinische Epidemiologie am Leibniz-Institut für Präventionsforschung und Epidemiologie – BIPS
  • 2010-2015 Arbeitsgruppenleiterin am Nationalen Centrum für Tumorerkrankungen (NCT) / Deutschen Krebsforschungszentrum (DKFZ) Heidelberg
  • 03/2013 Habilitation und Venia Legendi im Fach Epidemiologie an der Medizinischen Fakultät der Universität Heidelberg
  • 2008-2009 Visiting Assistant Professor, Division of Health Policy and Management, School of Public Health, University of Minnesota, USA
  • 2006-2010 Wissenschaftliche Mitarbeiterin am Deutschen Krebsforschungszentrum (DKFZ) Heidelberg
  • 07/2006 Promotion zum Dr. sc. Hum. An der Medizinischen Fakultät der Universität Heidelberg („summa cum laude”)
  • 2002-2005 Promotionsprogramm im Rahmen des DFG-geförderten Graduiertenkollegs 793 (Epidemiologie) an der Universität Heidelberg und wissenschaftliche Mitarbeiterin am Deutschen Zentrum für Alterns-forschung, Heidelberg
  • 01/2003 Approbation als Apothekerin
  • 2001-2002 Praktisches Jahr in der öffentlichen Apotheke (Heidelberg) und Industrie (Karlsruhe)
  • 1997-2001 Studium der Pharmazie an der Universität Würzburg
ORCID iD: https://orcid.org/0000-0002-1886-2923

Forschungsinteressen

  • Epidemiologie und Früherkennung des kolorektalen Karzinoms, Evaluation von Testverfahren und Programmen zur Krebsfrüherkennung, Krebsprävention in Risikogruppen, Pharmakoepidemiologie

Mitgliedschaft in Fachgesellschaften

Projekte

Ausgewählte Veröffentlichungen

  • Zeitschriftenartikel mit peer-review

  • Haug U, Riedel O, Cholmakow-Bodechtel C, Olsson L. First-degree relatives of cancer patients: A target group for primary prevention? A cross-sectional study. British Journal of Cancer. 2018;118(9):1255-1261.
    http://dx.doi.org/10.1038/s41416-018-0057-2
  • Plath J, Siebenhofer A, Haug U, Koné I, Hechtner M, Blumenstein I, Schulz-Rothe S, Gerlach FM, Guethlin C. Utilization of colonoscopy and colonoscopic findings among individuals aged 40-54 years with a positive family history of colorectal cancer: A cross-sectional study in general practice. European Journal of Cancer Prevention. 2018;27(6):539-545.
    http://dx.doi.org/10.1097/CEJ.0000000000000399
  • Wentzell N, Haug U, Schink T, Engel S, Liebentraut J, Linder R, Onken M, Schaefer C, Dathe K. Valproatverordnungen bei Mädchen und Frauen im gebärfähigen Alter in Deutschland: Untersuchung zeitlicher Trends basierend auf Versichertendaten. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2018;61(8):1022-1029.
    http://dx.doi.org/10.1007/s00103-018-2768-1
  • Haug U, Grobbee EJ, Lansdorp-Vogelaar I, Spaander MCW, Kuipers EJ. Immunochemical faecal occult blood testing to screen for colorectal cancer: Can the screening interval be extended? Gut. 2017;66(7):1262-1267.
    http://dx.doi.org/10.1136/gutjnl-2015-310102
  • Zia Shams A, Haug U. Strategies for prevention of gastrointestinal cancers in developing countries: A systematic review. Journal of Global Health. 2017;7(2):020405.
    http://dx.doi.org/10.7189/jogh.07.020405
  • Fiederling J, Zia Shams A, Haug U. Validity of self-reported family history of cancer: A systematic literature review on selected cancers. International Journal of Cancer. 2016;139(7):1449-1460.
    http://dx.doi.org/10.1002/ijc.30203
  • Haug U, Becker N. Immunologische Stuhlbluttests zur Darmkrebsfrüherkennung: Schnelltests sind keine vertretbare Option für ein qualitätsgesichertes Programm. Deutsche Medizinische Wochenschrift. 2016;141(10):729-731.
    http://dx.doi.org/10.1055/s-0042-104048
  • Young GP, Senore C, Mandel JS, Allison JE, Atkin WS, Benamouzig R, Bossuyt P, De Silva M, Guittet L, Halloran SP, Haug U, Hoff G, Itzkowitz SH, Leja M, Levin B, Meijer GA, O'Morain CA, Parry S, Rabeneck L, Rozen P, Saito H, Schoen RE, Seaman HE, Steele RJC, Sung JJY, Winawer SJ. Recommendations for a step-wise comparative approach to the evaluation of new screening tests for colorectal cancer. Cancer. 2016;122(6):826-839.
    http://dx.doi.org/10.1002/cncr.29865
  • Hermann S, Friedrich S, Haug U, Rohrmann S, Becker N, Kaaks R. Association between socio-economic and demographic characteristics and utilization of colonoscopy in the EPIC-Heidelberg cohort. European Journal of Cancer Prevention. 2015;24(2):81-88.
    http://dx.doi.org/10.1097/CEJ.0000000000000080
  • Fiederling J, Ulrich C, Hemminki K, Haug U. Consideration of family history of cancer in medical routine: A survey in the primary care setting in Germany. Eur J Cancer Prev. 2014;23(3):199-205.
    http://dx.doi.org/10.1097/CEJ.0b013e328364743d
  • Haug U, Engel S, Verheyen F, Linder R. Estimating colorectal cancer treatment costs: A pragmatic approach exemplified by health insurance data from Germany. PLOS ONE. 2014;9(2):e88407.
    http://dx.doi.org/10.1371/journal.pone.0088407
  • Haug U, Knudsen AB, Lansdorp-Vogelaar I, Kuntz KM. Development of new non-invasive tests for colorectal cancer screening: The relevance of information on adenoma detection. International Journal of Cancer. 2014;136(12):2864-2874.
    http://dx.doi.org/10.1002/ijc.29343
  • Haug U, Rösch T, Hoffmeister M, Katalinic A, Brenner H, Becker N. Einführung eines organisierten Darmkrebs-Screenings in Deutschland: Chancen und Herausforderungen. Das Gesundheitswesen. 2014;77(11):869-874.
    http://dx.doi.org/10.1055/s-0034-1377027
  • Ordonez-Mena JM, Schöttker B, Haug U, Muller H, Kohrle J, Schomburg L, Holleczek B, Brenner H. Serum 25-hydroxyvitamin D and cancer risk in older adults: Results from a large German prospective cohort study. Cancer Epidemiology, Biomarkers & Prevention. 2013;22(5):905-916.
    http://dx.doi.org/10.1158/1055-9965.EPI-12-1332
  • Perna L, Butterbach K, Haug U, Schöttker B, Müller H, Arndt V, Holleczek B, Burwinkel B, Brenner H. Vitamin D receptor genotype rs731236 (Taq1) and breast cancer prognosis. Cancer Epidemiology, Biomarkers & Prevention. 2013;22(3):437-442.
    http://dx.doi.org/10.1158/1055-9965.EPI-12-0970-T
  • Perna L, Felix JF, Breitling LP, Haug U, Raum E, Burwinkel B, Schöttker B, Brenner H. Genetic variations in the vitamin D binding protein and season-specific levels of vitamin D among older adults. Epidemiology. 2013;24(1):104-109.
    http://dx.doi.org/10.1097/EDE.0b013e318276c4b0
  • Perna L, Hoffmeister M, Schöttker B, Arndt V, Haug U, Holleczek B, Burwinkel B, Ordonez-Mena JM, Brenner H. Vitamin D receptor polymorphism and colorectal cancer-specific and all-cause mortality. Cancer Epidemiology. 2013;37(6):905-907.
    http://dx.doi.org/10.1016/j.canep.2013.09.007
  • Schöttker B, Haug U, Schomburg L, Köhrle J, Perna L, Müller H, Holleczek B, Brenner H. Strong associations of 25-hydroxyvitamin D concentrations with all-cause, cardiovascular, cancer, and respiratory disease mortality in a large cohort study. The American Journal of Clinical Nutrition. 2013;97(4):782-793.
    http://dx.doi.org/10.3945/ajcn.112.047712
  • Bünger S, Haug U, Kelly M, Posorski N, Klempt-Giessing K, Cartwright A, Fitzgerald SP, Toner V, McAleer D, Gemoll T, Laubert T, Büning J, Fellermann K, Bruch H-P, Roblick UJ, Brenner H, von Eggeling F, Habermann JK. A novel multiplex-protein array for serum diagnostics of colon cancer: A case-control study. BMC Cancer. 2012;12:393.
    http://dx.doi.org/10.1186/1471-2407-12-393
  • Haug U, Knudsen AB, Kuntz KM. How should individuals with a false-positive fecal occult blood test for colorectal cancer be managed? A decision analysis. International Journal of Cancer. 2012;131(9):2094-2102.
    http://dx.doi.org/10.1002/ijc.27463
  • Haug U, Poole EM, Xiao L, Curtin K, Duggan D, Makar KW, Peters U, Kulmacz RJ, Potter JD, Koepl L, Caan BJ, Slattery ML, Ulrich CM. Glutathione peroxidase tagSNPs: Associations with rectal cancer but not with colon cancer. Genes, Chromosomes & Cancer. 2012;51:598-605.
    http://dx.doi.org/10.1002/gcc.21946
  • Perna L, Haug U, Schöttker B, Müller H, Raum E, Jansen E, Brenner H. Public health implications of standardized 25-hydroxyvitamin D levels: A decrease in the prevalence of vitamin D deficiency among older women in Germany. Preventive Medicine. 2012;55(3):228-232.
    http://dx.doi.org/10.1016/j.ypmed.2012.06.010
  • Schöttker B, Jansen EH, Haug U, Schomburg L, Köhrle J, Brenner H. Standardization of misleading immunoassay based 25-hydroxyvitamin D levels with liquid chromatography tandem-mass spectrometry in a large cohort study. PLOS ONE. 2012;7(e48774)
    http://dx.doi.org/10.1371/journal.pone.0048774
  • Stock C, Pulte D, Haug U, Brenner H. Subsite-specific colorectal cancer risk in the colorectal endoscopy era. Gastrointestinal Endoscopy. 2012;75(3):621-630.
    http://dx.doi.org/10.1016/j.gie.2011.10.025
  • Tao S, Haug U, Kuhn K, Brenner H. Comparison and combination of blood-based inflammatory markers with faecal occult blood tests for non-invasive colorectal cancer screening. British Journal of Cancer. 2012;106(8):1424-1430.
    http://dx.doi.org/10.1038/bjc.2012.104
  • Bünger S, Haug U, Kelly FM, Klempt-Giessing K, Cartwright A, Posorski N, Dibbelt L, Fitzgerald SP, Bruch H-P, Roblick UJ, von Eggeling F, Brenner H, Habermann JK, on behalf of the BMBF consortium "Colorectal Cancer Screening Chip". Toward standardized high-throughput serum diagnostics: Multiplex-protein array identifies IL-8 and VEGF as serum markers for colon cancer. Journal of Biomolecular Screening. 2011;16(9):1018-1026.
    http://dx.doi.org/10.1177/1087057111414894
  • Haug U, Brenner H, Knudsen AB, Kuntz KM. Is fecal occult blood testing more sensitive for left- than for right-sided colorectal neoplasia? A systematic review. Expert Review of Molecular Diagnostics. 2011;11(6):605-616.
    http://dx.doi.org/10.1586/erm.11.41
  • Haug U, Kuntz KM, Knudsen AB, Hundt S, Brenner H. Sensitivity of fecal occult blood testing for detecting left- vs right-sided advanced neoplasia. British Journal of Cancer. 2011;104:1779-1785.
    http://dx.doi.org/10.1038/bjc.2011.160
  • Stock C, Knudsen AB, Lansdorp-Vogelaar I, Haug U, Brenner H. Colorectal cancer mortality prevented by use and attributable to nonuse of colonoscopy. Gastrointestinal Endoscopy. 2011;73(3):435-443.
    http://dx.doi.org/10.1016/j.gie.2010.12.005
  • Tao S, Hundt S, Haug U, Brenner H. Sensitivity of blood-based tests for colorectal cancer detection: Impact of overrepresentation of advanced stage disease. The American Journal of Gastroenterology. 2011;106(2):242-253.
    http://dx.doi.org/10.1038/ajg.2010.393
  • Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: Circulating vitamin D and ovarian cancer risk. Gynecologic Oncology. 2011;121(2):369-375.
    http://dx.doi.org/10.1016/j.ygyno.2011.01.023
  • Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: Serum vitamin D and colorectal adenoma risk. Preventive Medicine. 2011;53(1-2):10-16.
    http://dx.doi.org/10.1016/j.ypmed.2011.05.013
  • Brenner H, Haug U, Arndt V, Stegmaier C, Altenhofen L, Hoffmeister M. Low risk of colorectal cancer and advanced adenomas more than 10 years after negative colonoscopy. Gastroenterology. 2010;138(3):870-876.
    http://dx.doi.org/10.1053/j.gastro.2009.10.054
  • Brenner H, Haug U, Hundt S. Inter-test agreement and quantitative cross-validation of immunochromatographical fecal occult blood tests. International Journal of Cancer. 2010;127(7):1643-1649.
    http://dx.doi.org/10.1002/ijc.25154
  • Brenner H, Haug U, Hundt S. Sex differences in performance of fecal occult blood testing. The American Journal of Gastroenterology. 2010;105(11):2457-2464.
    http://dx.doi.org/10.1038/ajg.2010.301
  • Brenner H, Hoffmeister M, Arndt V, Stegmaier C, Altenhofen L, Haug U. Protection from right- and left-sided colorectal neoplasms after colonoscopy: Population-based study. Journal of the National Cancer Institute. 2010;102(2):89-95.
    http://dx.doi.org/ 10.1093/jnci/djp436
  • Brenner H, Tao S, Haug U. Low dose aspirin use and performance of immunochemical fecal occult blood tests. JAMA. 2010;304(22):2513-2520.
    http://dx.doi.org/10.1001/jama.2010.1773
  • Haug U, Hundt S, Brenner H. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: Evaluation in the target population of screening and comparison with qualitative tests. The American Journal of Gastroenterology. 2010;105(3):682-690.
    http://dx.doi.org/10.1038/ajg.2009.668
  • Hoffmeister M, Schmitz S, Karmrodt E, Stegmaier C, Haug U, Arndt V, Brenner H. Male sex and smoking have a larger impact on the prevalence of colorectal neoplasia than family history of colorectal cancer. Clinical Gastroenterology and Hepatology. 2010;8(10):870-876.
    http://dx.doi.org/10.1016/j.cgh.2010.07.004
  • Sieverding M, Matterne U, Ciccarello L, Haug U. Colonoscopy use in a country with a long-standing colorectal cancer screening programme: Evidence from a large German survey. Zeitschrift für Gastroenterologie. 2010;48(12):1351-1357.
    http://dx.doi.org/10.1055/s-0029-1245611
  • Stock C, Haug U, Brenner H. Population-based prevalence estimates of history of colonoscopy or sigmoidoscopy: review and analysis of recent trends. Gastrointestinal Endoscopy. 2010;71(2):366-381.
    http://dx.doi.org/10.1016/j.gie.2009.06.018
  • Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: Serum vitamin D and breast cancer risk. European Journal of Cancer. 2010;46(12):2196-2205.
    http://dx.doi.org/10.1016/j.ejca.2010.03.037
  • Brenner H, Hoffmeister M, Brenner G, Altenhofen L, Haug U. Expected reduction of colorectal cancer incidence within 8 years after introduction of the German screening colonoscopy programme: Estimates based on 1,875,708 screening colonoscopies. European Journal of Cancer. 2009;45(11):2027-2033.
    http://dx.doi.org/10.1016/j.ejca.2009.02.017
  • Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Annals of Internal Medicine. 2009;150(3):162-169.
    http://dx.doi.org/10.7326/0003-4819-150-3-200902030-00005
  • Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: Longitudinal studies of serum vitamin D and colorectal cancer risk. Alimentary Pharmacology & Therapeutics. 2009;30(2):113-125.
    http://dx.doi.org/10.1111/j.1365-2036.2009.04022.x
  • Yin L, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis of longitudinal studies: Serum vitamin D and prostate cancer risk. Cancer Epidemiology. 2009;33(6):435-445.
    http://dx.doi.org/10.1016/j.canep.2009.10.014
  • Brenner H, Hoffmeister M, Haug U. Family history and age at initiation of colorectal cancer screening. The American Journal of Gastroenterology. 2008;103(9):2326-2331.
    http://dx.doi.org/10.1111/j.1572-0241.2008.01978.x
  • Brenner H, Hooffmeister M, Haug U. Should colorectal cancer screening start at the same age in European countries? Contributions from descriptive epidemiology. British Journal of Cancer. 2008;99(3):532-535.
    http://dx.doi.org/10.1038/sj.bjc.6604488
  • Haug U, Hundt S, Brenner H. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study. British Journal of Cancer. 2008;99(1):133-135.
    http://dx.doi.org/10.1038/sj.bjc.6604427
  • Haug U, Wente M, Seiler CM, Jesnowski R, Brenner H. Stool testing for the early detection of pancreatic cancer: Rationale and current evidence. Expert Review of Molecular Diagnostics. 2008;8(6):753-759.
    http://dx.doi.org/10.1586/14737159.8.6.753
  • Müller H, Haug U, Rothenbacher D, Stegmaier C, Brenner H. Evaluation of serum and urinary myeloid related protein-14 as a marker for early detection of prostate cancer. The Journal of Urology. 2008;180(4):1309-1313.
    http://dx.doi.org/10.1016/j.juro.2008.06.025
  • Brenner H, Hoffmeister M, Arndt V, Haug U. Gender differences in colorectal cancer: Implications for age at initiation of screening. British Journal of Cancer. 2007;96(5):828-831.
    http://dx.doi.org/10.1038/sj.bjc.6603628
  • Brenner H, Hoffmeister M, Stegmaier C, Brenner G, Altenhofen L, Haug U. Risk of progression of advanced adenomas to colorectal cancer by age and sex: Estimates based on 840,149 screening colonoscopies. Gut. 2007;56(11):1585-1589.
    http://dx.doi.org/10.1136/gut.2007.122739
  • Haug U, Hillebrand T, Bendzko P, Low M, Rothenbacher D, Stegmaier C, Brenner H. Mutant-enriched PCR and allele-specific hybridization reaction to detect K-ras mutations in stool DNA: High prevalence in a large sample of older adults. Clinical Chemistry. 2007;53(4):787-790.
    http://dx.doi.org/10.1373/clinchem.2006.078188
  • Haug U, Rothenbacher D, Wente MN, Seiler CM, Stegmaier C, Brenner H. Tumour M2-PK as a stool marker for colorectal cancer: Comparative analysis in a large sample of unselected older adults vs colorectal cancer patients. British Journal of Cancer. 2007;96(9):1329-1334.
    http://dx.doi.org/10.1038/sj.bjc.6603712
  • Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer: A systematic review. Cancer Epidemiology, Biomarkers & Prevention. 2007;16(10):1935-1953.
    http://dx.doi.org/10.1158/1055-9965.EPI-06-0994
  • Haug U, Wente MN, Seiler CM, Rothenbacher D, Buchler MW, Brenner H. Tumor-M2-PK as a stool marker for colorectal cancer: Stability at room temperature and implications for application in the screening setting. Clinical Chemistry. 2006;52(4):782-784.
    http://dx.doi.org/10.1373/clinchem.2005.062752
  • Haug U, Brenner H. New stool tests for colorectal cancer screening: A systematic review focusing on performance characteristics and practicalness. International Journal of Cancer. 2005;117(2):169-176.
    http://dx.doi.org/10.1002/ijc.21016
  • Haug U, Brenner H. A simulation model for colorectal cancer screening: Potential of stool tests with various performance characteristics compared to screening colonoscopy. Cancer Epidemiology, Biomarkers & Prevention. 2005;14(2):422-428.
    http://dx.doi.org/10.1158/1055-9965.EPI-04-0411
  • Editorials

  • Haug U. Flexible sigmoidoscopy screening for colorectal cancer. British Medical Journal. 2017;356:j75.
    http://dx.doi.org/10.1136/bmj.j75
  • Commentaries

  • Senore C, Haug U. Faecal immunochemical tests have the potential for correctly ruling out colorectal cancer in symptomatic patients. BMJ Evidence-Based Medicine. 2018;23(3):113-114.
    http://dx.doi.org/10.1136/bmjebm-2018-110901.

Weitere Publikationen finden Sie unter nachfolgendem Link:

Preise, Auszeichnungen und Ehrungen

  • Darmkrebs-Präventionspreis 2016 / Colorectal Cancer Prevention Award 2016
    Deutsche Krebsgesellschaft, Stiftung LebensBlicke und Deutsche Krebsstiftung (2016)
    Darmkrebsvorsorge und -früherkennung
  • Reisestipendium (travel grant) “Best submitted abstracts” / Oral Free Paper Prize
    United European Gastroenterology Week (2014)
  • Felix-Burda-Award for Medical Prevention
    Felix Burda Stiftung (2009)
    Förderung der Darmkrebsprävention und -früherkennung in Deutschland
  • Young Scientist Award (1st prize) of the German Epidemiological Association
    Deutsche Gesellschaft für Epidemiologie (2005)
  • Promotionsstipendium 2002-2005 / PhD scholarship
    Deutsche Forschungsgemeinschaft (2002)

Lehre

  • Master-Studiengang Epidemiologie der Universität Bremen
  • Bachelor-Studiengang Public Health/Pflegewissenschaft der Universität Bremen

Verantwortlich für den Inhalt dieser Seite ist Ulrike Haug.